On October 20, the innovative drug concept was active. According to the news, the National Development and Reform Commission revealed at a press conference that innovative drugs authorized foreign technology for the first three quarters of this year was about 130 billion US dollars, which is close to the whole of last year. Furthermore, there have been frequent reports of innovative pharmaceutical companies in recent days, which has also played a catalytic role in the popularity of investment in the sector. It is worth noting that from October 23 to 27, the 2026 Annual Meeting of the European Society of Medical Oncology was held in Madrid, Spain. A total of 29 innovative Chinese drug studies were selected for the latest breakthrough summary at this conference, accounting for about one-third of the total LBA of the conference, a record high; 5 of these studies reached the highest standard presidential seminar at the conference, achieving a double breakthrough in quantity and quality. Judging from the full-year performance forecast, out of concept stocks with net profit of 100 million yuan or more in the first half of the year, 15 shares received ratings from at least 10 institutions, and the institutions unanimously predicted that net profit for the full year of 2026 is expected to increase by more than 15%.

On October 20, the innovative drug concept was active. According to the news, the National Development and Reform Commission revealed at a press conference that innovative drugs authorized foreign technology for the first three quarters of this year was about 130 billion US dollars, which is close to the whole of last year. Furthermore, there have been frequent reports of innovative pharmaceutical companies recently, which has also played a catalytic role in the popularity of investment in the sector. It is worth noting that from October 23 to 27, the 2026 Annual Meeting of the European Society of Medical Oncology was held in Madrid, Spain. A total of 29 innovative Chinese drug studies were selected for the latest breakthrough summary at this conference, accounting for about one-third of the total LBA of the conference, a record high; 5 of these studies reached the highest standard presidential seminar at the conference, achieving a double breakthrough in quantity and quality. Judging from the full-year performance forecast, out of concept stocks with net profit of 100 million yuan or more in the first half of the year, 15 shares received ratings from at least 10 institutions, and the institutions unanimously predicted that net profit for the full year of 2026 is expected to increase by more than 15%.